Program Information


A Patient-Centric Symposium held during the
Annual Meeting of the European Society for Blood and Marrow Transplantation

Sunday, 30 August 2020
10:30 – 12:00



Hall: Sala Retiro
IFEMA Feria de Madrid
Madrid, Spain


DIFFICULT-TO-TREAT PATIENT CASES
Addressed by the Expert Panel

CLINICAL CASE-BASED SYMPOSIUM
Join us for cutting edge insights on clinically challenging cases of cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT) patients. Test your knowledge about CMV and learn about emerging therapies for minimizing bone marrow toxicity and improving outcomes.


10:00 – 10:30
 
Registration and Breakfast
10:30 – 10:35
 
Welcome and Introductions
Jan Styczynski, MD
10:35 – 11:05
 

Refractory CMV Disease
AND Panel Discussion
Per Ljungman, MD, PhD and Panel
11:05 – 11:10
 
Audience Q&A
11:10 – 11:40
 

Late CMV Disease
AND Panel Discussion
Johan Maertens, MD, PhD and Panel
11:40 – 12:00
 
Audience Q&A, Closing Remarks
All Faculty

Jan Styczynski, MD (Moderator)
Chairman, EBMT Infectious Diseases Working Party
Department of Pediatric Hematology and Oncology
Collegium Medicum
Nicolaus Copernicus University
Bydgoszcz, Poland
Per Ljungman, MD, PhD
Professor of Hematology
Karolinska University Hospital
Stockholm, Sweden
Johan Maertens, MD, PhD
Associate Professor of Hematology
University Hospitals Leuven
Leuven, Belgium



Upon completion of this educational activity, participants should be able to:

  • Select anti-CMV therapy in HCT patients using evidence-based therapeutic approaches and knowledge of emerging therapies in clinical trials
  • Manage CMV treatments in HCT patients based on viral load, side effect profile, and consideration of antiviral resistance
  • Differentiate between CMV recurrence, resistance, or late recurrence and implement appropriate therapies
  • Describe the burden of CMV infection in HCT patients, including the impact of CMV seropositivity and indirect effects


This educational activity is designed for practicing clinicians, including hematology and infectious disease specialist clinicians in the United States and Europe, who manage CMV infection and disease in HCT patients.



It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.



This activity is jointly provided by RMEI Medical Education and Advancing Knowledge in Healthcare.



This symposium is supported by an independent medical education grant from Takeda.



There is no fee for this educational activity.



Please contact Nicole Neely at nneely@rmei.com.





Facebook  Twitter  LinkedIn

Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.